Cost-Effectiveness and Cost–Utility Analyses in Thailand of Continuous Intrathecal Morphine Infusion Compared with Conventional Therapy in Cancer Pain: A 10-year Multicenter Retrospective Study

References

• van den Beuken-van Everdingen MH, Hochstenbach LM, Joosten EA, Tjan-Heijnen VC, Janssen DJ. Update on prevalence of pain in patients with cancer: systematic review and meta-analysis. J Pain Symptom Manage. 2016;51(6):1070–1090.e9. doi:10.1016/j.jpainsymman.2015.12.340.
   PubMed Web of Science ®Google Scholar
• Portenoy RK. Treatment of cancer pain. Lancet. 2011;377:2236–14. doi:10.1016/S0140-6736(11)60236-5.
   PubMed Web of Science ®Google Scholar
• NHS England. Clinical commissioning policy: intrathecal pumps for treatment of severe cancer pain; 2015. https://www.england.nhs.uk/commissioning/wp-content/uploads/sites/12/2015/10/d08pb-intra-pumps-trtmnt.pdf.
   Google Scholar
• Bruel BM, Burton AW. Intrathecal therapy for cancer-related pain. Pain Med. 2016;17(12):2404–21. doi:10.1093/pm/pnw060.
   PubMed Web of Science ®Google Scholar
• Smith TJ, Coyne PJ, Staats PS, Deer T, Stearns LJ, Rauck RL, Boortz-Marx RL, Buchser E, Catala E, Bryce DA, et al. An implantable drug delivery system (IDDS) for refractory cancer pain provides sustained pain control, less drug-related toxicity, and possibly better survival compared with comprehensive medical management (CMM). Ann Oncol. 2005;16(5):825–33. doi:10.1093/annonc/mdi156.
   PubMed Web of Science ®Google Scholar
• Qin W, Li Y, Liu B, Liu Y, Zhang Y, Zhang X, Li P, Fan B. Intrathecal morphine infusion therapy via a percutaneous port for refractory cancer pain in China: an efficacy, safety and cost utilization analysis. J Pain Res. 2020;13:231–37. doi:10.2147/JPR.S233905.
   PubMed Web of Science ®Google Scholar
• Brogan SE, Winter NB, Abiodun A, Safarpour R. A cost utilization analysis of intrathecal therapy for refractory cancer pain: identifying factors associated with cost benefit. Pain Med. 2013;14(4):478–86. doi:10.1111/pme.12060.
   PubMed Web of Science ®Google Scholar
• Dupoiron D. Intrathecal therapy for pain in cancer patients. Curr Opin Support Palliat Care. 2019;13(2):75–80. doi:10.1097/SPC.0000000000000427.
   PubMed Web of Science ®Google Scholar
• Kiehelä L, Hamunen K, Heiskanen T. Spinal analgesia for severe cancer pain: a retrospective analysis of 60 patients. Scand J Pain. 2017;16:140–45. doi:10.1016/j.sjpain.2017.04.073.
   PubMedGoogle Scholar
• Health Quality Ontario. Intrathecal drug delivery systems for cancer pain: a health technology assessment. Ont Health Technol Assess Ser. 2016;16(1):1–51.
   Google Scholar
• Kim EK, Shin JY, Castaneda AM, Lee SJ, Yoon HY, Kim YC, Moon JY. Retrospective analysis of the financial break-even point for intrathecal morphine pump use in Korea. Korean J Pain. 2017;30(4):272–80. doi:10.3344/kjp.2017.30.4.272.
   PubMed Web of Science ®Google Scholar
• Bruera E, Schoeller T, Wenk R, MacEachern T, Marcelino S, Hanson J, Suarez-Almazor M. A prospective multicenter assessment of the Edmonton staging system for cancer pain. J Pain Symptom Manage. 1995;10(5):348–55. doi:10.1016/0885-3924(95)00052-Z.
   PubMed Web of Science ®Google Scholar
• Dowell D, Ragan KR, Jones CM, Baldwin GT, Chou R. CDC clinical practice guideline for prescribing opioids for pain - United States, 2022. MMWR Recomm Rep. 2022 Nov 4;71(3):1–95. doi:10.15585/mmwr.rr7103a1.
   PubMed Web of Science ®Google Scholar
• Deer TR, Pope JE, Hayek SM, Bux A, Buchser E, Eldabe S, De Andres JA, Erdek M, Patin D, Grider JS, et al. The Polyanalgesic Consensus Conference (PACC): recommendations on intrathecal drug infusion systems best practices and guidelines. Neuromodulation. 2017;20(2):96–132. doi:10.1111/ner.12538.
   PubMed Web of Science ®Google Scholar
• Chewaskulyong B, Sapinun L, Downing GM, Intaratat P, Lesperance M, Leautrakul S, Somwangprasert A, Leerapun T. Reliability and validity of the Thai translation (Thai PPS Adult Suandok) of the Palliative Performance Scale (PPSv2). Palliat Med. 2012;26:1034–41. doi:10.1177/0269216311424633.
   PubMed Web of Science ®Google Scholar
• Pattanaphesaj J, Thavorncharoensap M, Ramos-Goñi JM, Tongsiri S, Ingsrisawang L, Teerawattananon Y. The EQ-5D-5L valuation study in Thailand. Expert Rev Pharmacoecon Outcomes Res. 2018;18(5):551–58. doi:10.1080/14737167.2018.1494574.
   PubMed Web of Science ®Google Scholar
• Cai D, Shi S, Jiang S, Si L, Wu J, Jiang Y. Estimation of the cost-effective threshold of a quality-adjusted life year in China based on the value of statistical life. Eur J Health Econ. 2022;23(4):607–15. doi:10.1007/s10198-021-01384-z.
   PubMed Web of Science ®Google Scholar
• Tanvejsilp P, Taychakhoonavudh S, Chaikledkaew U, Chaiyakunapruk N, Ngorsuraches S. Revisiting roles of health technology assessment on drug policy in universal health coverage in Thailand: where are we? and what is next? Value Health Reg Issues. 2019;18:78–82. doi:10.1016/j.vhri.2018.11.004.
   PubMedGoogle Scholar
• Dworkin RH, Turk DC, Wyrwich KW, Beaton D, Cleeland CS, Farrar JT, Haythornthewaite JA, Jensen MP, Kerns RD, Ader DN. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J Pain. 2008;9(2):105–21. doi:10.1016/j.jpain.2007.09.005.
   PubMed Web of Science ®Google Scholar
• Vanness DJ, Lomas J, Ahn H. A health opportunity cost threshold for cost-fffectiveness analysis in the United States. Ann Intern Med. 2021;174(1):25–32. doi:10.7326/M20-1392.
   PubMed Web of Science ®Google Scholar
• Necking E, Levi R, Ertzgaard P. Complications of intrathecal drug delivery therapy (ITDD): a retrospective study of 231 implantations between 1999 and 2014. Clin Neurol Neurosurg. 2021;205:106630. doi:10.1016/j.clineuro.2021.106630.
   PubMed Web of Science ®Google Scholar
• Kim EJ, Moon JY, Kim YC, Park KS, Yoo YJ. Intrathecal morphine infusion therapy in management of chronic pain: present and future implementation in Korea. Yonsei Med J. 2016;57(2):475–81. doi:10.3349/ymj.2016.57.2.475.
   PubMed Web of Science ®Google Scholar
• Kumar K, Hunter G, Demeria DD. Treatment of chronic pain by using intrathecal drug therapy compared with conventional pain therapies: a cost-effectiveness analysis. J Neurosurg. 2002;97(4):803–10. doi:10.3171/jns.2002.97.4.0803.
   PubMed Web of Science ®Google Scholar
• Bhatia G, Lau ME, Koury KM, Gulur P. Intrathecal Drug Delivery (ITDD) systems for cancer pain. F1000Res. 2013;2:96. doi:10.12688/f1000research.2-96.v4.
   PubMedGoogle Scholar
• Deer TR, Pope JE, Hanes MC, McDowell GC. Intrathecal therapy for chronic pain: a review of morphine and ziconotide as firstline options. Pain Med. 2019;20(4):784–98. doi:10.1093/pm/pny132.
   PubMed Web of Science ®Google Scholar
• Sela RA, Bruera E, Conner-spady B, Cumming C, Walker C. Sensory and affective dimensions of advanced cancer pain. Psychooncology. 2002;11(1):23–34. doi:10.1002/pon.551.
   PubMed Web of Science ®Google Scholar
• Stearns LJ, Narang S, Albright RE Jr, Hammond K, Xia Y, Richter HB, Paramanandam GK, Haagensen KK, Doth AH. Assessment of health care utilization and cost of targeted drug delivery and conventional medical management vs conventional medical management alone for patients with cancer-related pain [published correction appears in JAMA Netw Open. 2019;2(5):e195248]. JAMA Netw Open. 2019;2(4):e191549. doi:10.1001/jamanetworkopen.2019.1549.
   PubMed Web of Science ®Google Scholar
• Menzel PT. How should willingness-to-pay values of quality-adjusted life-years be updated and according to whom? AMA J Ethics. 2021;23(8):E601–E606. doi:10.1001/amajethics.2021.601.
   PubMedGoogle Scholar
• De Andres J, Rubio-Haro R, Andres-serrano CD, Asensio-Samper JM, Fabregat-Cid G. Intrathecal drug delivery. Methods Mol Biol. 2020;2059:75–108.
   PubMedGoogle Scholar
• Aman MM, Mahmoud A, Deer T, Sayed D, Hagedorn JM, Brogan SE, Singh V, Gulati A, Strand N, Weisbein J, et al. The American Society of Pain and Neuroscience (ASPN) best practices and guidelines for the interventional management of cancer-associated pain. J Pain Res. 2021;14:2139–64. doi:10.2147/JPR.S315585.
   PubMed Web of Science ®Google Scholar
• Mishra S, Bhatnagar S, Chaudhary P, Rana SP. Breakthrough cancer pain: review of prevalence, characteristics and management. Indian J Palliat Care. 2009;15(1):14–18. doi:10.4103/0973-1075.53506.
   PubMedGoogle Scholar
• McCarberg BH. The treatment of breakthrough pain. Pain Med. 2007;8(Suppl 1):S8–13. doi:10.1111/j.1526-4637.2006.00270.x.
   PubMed Web of Science ®Google Scholar
• Brant JM, Rodgers BB, Gallagher E, Sundaramurthi T. Breakthrough cancer pain: a systematic review of pharmacologic management. Clin J Oncol Nurs. 2017;21(3):71–80. doi:10.1188/17.CJON.S3.71-80. PMID: 28524907.
   PubMed Web of Science ®Google Scholar
• Cascella M, Monaco F, Nocerino D, Chinè E, Carpenedo R, Picerno P, Migliaccio L, Armignacco A, Franceschini G, Coluccia S, et al. A bibliometric network analysis on rapid-onset opioids for breakthrough cancer pain treatment. J Pain Symptom Manage. 2022;63(6):1041–50. doi:10.1016/j.jpainsymman.2022.01.023. PMID:35151801.
   PubMed Web of Science ®Google Scholar
• Mercadante S. Treating breakthrough pain in oncology. Expert Rev Anticancer Ther. 2018;18(5):445–49. doi:10.1080/14737140.2018.1443813. PMID:29478355.
   PubMed Web of Science ®Google Scholar